Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23 Colorectal Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 2 Stomach Neoplasms 1 Solid Tumors 1 Solid Tumor, Adult 1 Salivary Gland Neoplasms 1 RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Non-small Cell Lung Cancers 1 Lung Neoplasms 1 Locally Recurrent Skin Squamous Cell Carcinoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoma, Adenoid Cystic 1 Breast Neoplasms 1

Interventions

pembrolizumab 180 Gemcitabine 168 Paclitaxel 150 Carboplatin 134 Bevacizumab 126 Cisplatin 113 Docetaxel 112 Cyclophosphamide 109 Exercise 97 Nivolumab 92 Fluorouracil 88 Capecitabine 85 Dexamethasone 81 Irinotecan 74 Radiotherapy 68 Oxaliplatin 68 Pemetrexed 66 Standard of Care 64 Leucovorin 63 Cetuximab 59 Sorafenib 53 Erlotinib Hydrochloride 53 Drug Therapy 53 Blood Specimen Collection 52 Doxorubicin 50 trametinib 47 atezolizumab 47 Ipilimumab 47 Albumin-Bound Paclitaxel 44 130-nm albumin-bound paclitaxel 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × amivantamab × Clear all

NCT03767075 2024-04-25

BoB

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡